Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

Publication | Open Access

DOI Full Paper Access

181

Citations

References

2016

Year

Marcus J. Drake, Christopher R. Chapple, Adil Esen, Stavros Athanasiou, J. Cambronero, David Mitcheson, Sender Herschorn, Tahir Saleem, Moses Huang, Emad Siddiqui,

European Urology